肿瘤间质比对肿瘤预后的评价作用

doi:10.3760/cma.j.issn.1673-422X.2015.04.012

摘要/Abstract

摘要： 肿瘤间质比（TSR）指肿瘤组织内肿瘤细胞与间质部分的比例，可通过对苏木素-伊红染色的病理切片进行评估得到。通常以50%作为截断值，将病例分为间质丰富组（TSR＜50%）及间质稀少组（TSR≥50%），从而比较两组患者的预后差异。当前研究结果表明，在结直肠癌、乳腺癌、食管癌、宫颈癌和非小细胞肺癌中，TSR是肿瘤预后的独立影响因子，肿瘤间质丰富的患者预后更差，原因可能为肿瘤细胞能活化间质细胞，而活化的间质细胞又能促进肿瘤的生长、浸润及转移，间质组织在肿瘤的进展及侵袭过程中起着必不可少的作用。

关键词: 肿瘤, 预后, 肿瘤间质比

Abstract: Tumorstroma ratio is the ratio of tumor cells and stromal tissue. It can be evaluated through HEstained sections. Usually a 50% cutoff value is taken. TSR is stratified as stroma rich (TSR<50%) and stroma poor (TSR≥50%). The different prognosis between the two groups can be assessed. Several previous studies show that TSR is an independent prognostic factor for colon carcinoma, breast cancer, esophageal squamous cell carcinoma, cervical carcinoma and nonsmall cell lung cancer; patients with stromarich tumor suffer worse prognosis. The cause might be that tumor cells could activate stroma cells while activated stroma cells could promote the growth, infiltration and metastasis of tumors. And tumor stroma should be recognized as an indispensible participant in progression and invasion of carcinoma.

Key words: Neoplasmas, Prognosis, Tumor-stroma ratio

蔡贤磊；吴健；郑树森. 肿瘤间质比对肿瘤预后的评价作用[J]. 国际肿瘤学杂志, 2015, 42(4): 284-287.

CAI Xian-Lei-；Wu-Jian-；Zheng-Shu-Sen. Effect of tumor-stroma ratio in prognosis evaluation of tumor[J]. Journal of International Oncology, 2015, 42(4): 284-287.

参考文献

［1］ Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma［J］. Exp Cell Res, 2010, 316(8):13241331. ［2］ Astekar M, Metgud R, Sharma A, et al. Hidden keys in stroma: Unlocking the tumor progression［J］. J Oral Maxillofac Pathol, 2013, 17(1):8288. ［3］ Karagiannis GS, Poutahidis T, Erdman SE, et al. Cancerassociated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue［J］. Mol Cancer Res, 2012, 10(11):14031418. ［4］ Bremnes RM, Donnem T, AlSaad S, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinomaassociated fibroblasts and nonsmall cell lung cancer［J］. J Thorac Oncol, 2011, 6(1):209217. ［5］ Huijbers A, Tollenaar RA, v Pelt GW, et al. The proportion of tumorstroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial［J］. Ann Oncol, 2013, 24(1):179185. ［6］ de Kruijf EM, van Nes JG, van de Velde CJ, et al. Tumorstroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triplenegative carcinoma patients［J］. Breast Cancer Res Treat, 2011, 125(3):687696. ［7］ Dekker TJ, van de Velde CJ, van Pelt GW, et al. Prognostic significance of the tumorstroma ratio: validation study in nodenegative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)［J］. Breast Cancer Res Treat, 2013, 139(2):371379. ［8］ Wang K, Ma W, Wang J, et al. Tumorstroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma［J］. J Thorac Oncol, 2012, 7(9):14571461. ［9］ Courrech Staal EF, Smit VT, van Velthuysen ML, et al. Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies［J］. Eur J Cancer, 2011, 47(3):375382. ［10］ Liu J, Liu J, Li J, et al. Tumorstroma ratio is an independent predictor for survival in early cervical carcinoma［J］. Gynecol Oncol, 2014, 132(1):8186. ［11］王兆峰, 刘红兵, 赵仁德, 等. 肿瘤间质比是非小细胞肺癌独立的预后因素［J］. 中国肺癌杂志, 2013, 16(4): 191196. ［12］ Hemmings C. Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis［J］. Pathology, 2013, 45(4):371381. ［13］ Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma［J］. Semin Oncol, 2014, 41(2):217234. ［14］ Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma［J］. World J Gastroenterol, 2014, 20(7):16671680. ［15］ Gupta DK, Singh N, Sahu DK. TGFbeta mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma［J］. Cancer Growth Metastasis, 2014, 7:18. ［16］ Erez N, Truitt M, Olson P, et al. Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumorpromoting inflammation in an NFkappaBdependent manner［J］. Cancer Cell, 2010, 17(2):135147. ［17］ Balsamo M, Scordamaglia F, Pietra G, et al. Melanomaassociated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity［J］. Proc Natl Acad Sci U S A, 2009, 106(49):2084720852. ［18］ Calon A, Tauriello DV, Batlle E. TGFbeta in CAFmediated tumor growth and metastasis［J］. Semin Cancer Biol, 2014, 25:1522. ［19］ Reichl P, Haider C, Grubinger M, et al. TGFbeta in epithelial to mesenchymal transition and metastasis of liver carcinoma［J］. Curr Pharm Des, 2012, 18(27):41354147. ［20］潘漪莲. 上皮细胞间质转化与肿瘤［J］. 国际肿瘤学杂志, 2010, 37(5): 348351. ［21］强素凤, 黄勇. 上皮细胞间质转化与肿瘤干细胞［J］. 国际肿瘤学杂志, 2013, 40(3): 177180. ［22］ Eiró N, Vizoso FJ. Inflammation and cancer［J］. World J Gastrointest Surg, 2012, 4(3):6272. ［23］ Gong Y, ChippadaVenkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression［J］. Cancers (Basel), 2014, 6(3):12981327. ［24］ Zhao H, Yuan X, Jiang J, et al. Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases9 and NFκB activity［J］. Basic Clin Pharmacol Toxicol, 2014, 115(6): 527533.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.